$220.79
5.732.66%
In chiusura: Feb 13, 4:00 PM EST
$220.79
N/A
Post-mercato: 4:00 PM EST
sabato, febbraio 14
Comments
Loading...
Attività di insider trading
Tieni traccia delle ultime attività di insider trading Cardinal Health. Rimani informato sui recenti acquisti, vendite e impatto sul mercato per le azioni Cardinal Health.
Cos'è l'attività interna?
L'attività di insider trading coinvolge soggetti interni all'azienda, come dirigenti, direttori e dipendenti, impegnati in transazioni sulle azioni della propria azienda. Le transazioni di acquisto e vendita degli addetti ai lavori forniscono informazioni preziose sulla loro fiducia nelle prestazioni future dell'azienda.
Cosa stanno facendo gli Cardinal Health Inc addetti ai lavori?
A Cardinal Health Inc, la recente attività interna ha attirato l'attenzione. Negli ultimi 30 giorni, gli addetti ai lavori hanno riferito di aver venduto un totale di 4.00K azioni del valore di $918.88K, nel frattempo, gli addetti ai lavori hanno segnalare nessun acquisto negli ultimi 30 giorni.
Notevoli acquisti e vendite recenti di insider
- Il giorno febbraio 10, 2026, Hemingway Patricia Hall, l'azienda DIRECTOR sold 4K condivisioni per 229.72 ciascuna.
Statistiche sulla proprietà per Cardinal Health Inc
Numero di azioni emesse
235.316M
Azioni liquide
203911839.0%
Azioni possedute dagli insider
5.492M
Percentuale posseduta dagli Insider
2.31%
Azioni possedute dagli investitori istituzionali
133.469M
Percentuale posseduta dagli investitori istituzionali
56.7%
| Feb 10, 2026 | Hemingway Patricia Hall | DIRECTOR | -4.00K | $229.72 | -$918.88K | SELL | -12.40% | 28.26K | Feb 06 | View |
| Aug 20, 2025 | DEBORAH WEITZMAN | CEO, PSS SEGMENT | -21.37K | $150.53 | -$3.22M | SELL | -28.57% | 53.43K | Aug 20 | View |
| Aug 20, 2025 | Jason Hollar | CHIEF EXECUTIVE OFFICER | -35.90K | $150.04 | -$5.39M | SELL | -15.22% | 200.00K | Aug 20 | View |
| Aug 19, 2025 | Mary Scherer | CHIEF ACCOUNTING OFFICER | -8.13K | $149.52 | -$1.40M | SELL | -69.58% | 3.56K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Michelle Greene | CHIEF INFORMATION OFFICER | -19.99K | $149.41 | -$3.51M | SELL | -57.17% | 14.98K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Stephen Mason | CEO, GMPD SEGMENT | -63.43K | $149.41 | -$10.82M | SELL | -70.86% | 26.09K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Jason Hollar | CHIEF EXECUTIVE OFFICER | -201.33K | $149.64 | -$36.53M | SELL | -46.05% | 235.90K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Jessica Mayer | CHIEF LEGAL/COMPLIANCE OFFICER | -56.65K | $149.41 | -$9.86M | SELL | -53.90% | 48.46K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Aaron Alt | CHIEF FINANCIAL OFFICER | -71.75K | $149.38 | -$12.41M | SELL | -70.07% | 30.65K | Aug 15 - Aug 19 | View |
| Aug 19, 2025 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | -39.92K | $149.44 | -$6.92M | SELL | -71.93% | 15.57K | Aug 15 - Aug 19 | View |
| Nov 14, 2024 | Mary Scherer | CHIEF ACCOUNTING OFFICER | -3.50K | $123.55 | -$432.92K | SELL | -28.59% | 8.75K | Nov 14 | View |
| Aug 22, 2024 | Jessica Mayer | CHIEF LEGAL/COMPLIANCE OFFICER | -16.57K | $109.39 | -$1.81M | SELL | -17.91% | 75.97K | Aug 21 | View |
| Aug 19, 2024 | Jessica Mayer | CHIEF LEGAL/COMPLIANCE OFFICER | -18.52K | $89.63 | -$3.49M | SELL | -16.68% | 92.54K | Aug 15 - Aug 16 | View |
| Aug 19, 2024 | Aaron Alt | CHIEF FINANCIAL OFFICER | 9.47K | $108.39 | -$520.72K | GRANT | 34.55% | 36.87K | Aug 15 - Aug 19 | View |
| Aug 19, 2024 | Michelle Greene | CHIEF INFORMATION OFFICER | -3.03K | $107.92 | -$846.99K | SELL | -13.60% | 19.24K | Aug 15 - Aug 19 | View |
| Aug 19, 2024 | Jason Hollar | CHIEF EXECUTIVE OFFICER | -63.13K | $108.18 | -$12.04M | SELL | -24.21% | 197.64K | Aug 15 - Aug 19 | View |
| Aug 19, 2024 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | -26.57K | $92.83 | -$4.26M | SELL | -49.00% | 27.66K | Aug 15 - Aug 19 | View |
| Aug 19, 2024 | Stephen Mason | CEO, GMPD SEGMENT | -42.64K | $95.98 | -$6.29M | SELL | -51.18% | 40.67K | Aug 15 - Aug 19 | View |
| Nov 29, 2023 | DEBORAH WEITZMAN | CEO, PHARMACEUTICAL SEGMENT | -9.00K | $90.21 | -$1.85M | SELL | -20.36% | 35.20K | Nov 27 | View |
| Aug 29, 2023 | DEBORAH WEITZMAN | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $80.62 | -$123.37K | SELL-OPTIONS | 0.00% | 44.20K | Aug 28 | View |
| Aug 21, 2023 | Mary Scherer | CHIEF ACCOUNTING OFFICER | -9.23K | $80.82 | -$921.71K | SELL | -46.44% | 10.65K | Aug 18 | View |
| Aug 17, 2023 | Jessica Mayer | CHIEF LEGAL/COMPLIANCE OFFICER | -45.43K | $84.17 | -$5.37M | SELL | -34.87% | 84.86K | Aug 15 - Aug 17 | View |
| Aug 17, 2023 | Stephen Mason | CEO, MEDICAL SEGMENT | -49.93K | $89.63 | -$5.66M | SELL | -57.20% | 37.35K | Aug 15 - Aug 17 | View |
| Aug 17, 2023 | Michelle Greene | CHIEF INFORMATION OFFICER | 7.16K | $89.16 | -$288.79K | GRANT | 52.43% | 20.81K | Aug 15 - Aug 17 | View |
| Aug 17, 2023 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | -28.03K | $80.43 | -$3.42M | SELL | -52.50% | 25.36K | Aug 15 - Aug 17 | View |
| Aug 08, 2023 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | 23.29K | $50.35 | $16.31K | BUY | 77.39% | 53.39K | Oct 15 - Aug 07 | View |
| Nov 16, 2022 | Michelle Brennan | DIRECTOR | 400.00 | $75.51 | $30.20K | BUY | 13.68% | 3.32K | Nov 14 - Nov 15 | View |
| Nov 10, 2022 | Michelle Brennan | DIRECTOR | 2.46K | $79.74 | $11.96K | BUY | 527.47% | 2.92K | Nov 09 - Nov 10 | View |
| Nov 09, 2022 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | -20.22K | $78.87 | -$1.55M | SELL | -39.71% | 30.70K | Nov 07 | View |
| Nov 09, 2022 | Stephen Mason | CEO, MEDICAL SEGMENT | -44.35K | $74.34 | -$3.81M | SELL | -47.51% | 49.00K | Nov 07 | View |
| Nov 19, 2021 | Ola Snow | CHIEF HUMAN RESOURCES OFFICER | -10.00K | $49.17 | -$491.70K | SELL | -21.23% | 37.11K | Nov 18 | View |
| Mar 01, 2021 | Jessica Mayer | CHIEF LEGAL/COMPLIANCE OFFICER | -3.50K | $51.53 | -$180.35K | SELL | -21.72% | 12.62K | Feb 26 | View |
| Feb 12, 2021 | Patricia English | CHIEF ACCOUNTING OFFICER | -3.29K | $51.98 | -$171.07K | SELL | -35.10% | 6.08K | Feb 11 | View |
| Nov 13, 2018 | STUART LAWS | SVP & CHIEF ACCOUNTING OFFICER | -804.00 | $55.55 | -$44.66K | SELL | -11.32% | 6.30K | Nov 12 - Nov 13 | View |
| Aug 21, 2018 | Jon Giacomin | CEO, MEDICAL SEGMENT | -2.89K | $51.95 | -$150.14K | SELL | -3.83% | 72.65K | Aug 20 | View |
| Feb 20, 2018 | Jon Giacomin | CEO, MEDICAL SEGMENT | 6.69K | $68.78 | -$549.92K | GRANT | 13.83% | 55.05K | Feb 15 - Feb 20 | View |
| Feb 16, 2018 | PATRICIA MORRISON | CHIEF INFORMATION OFFICER | -29.71K | $66.34 | -$1.97M | SELL | -45.93% | 34.98K | Feb 14 - Feb 15 | View |
| Jan 23, 2018 | Michael Kaufmann | CHIEF EXECUTIVE OFFICER | -18.59K | $73.90 | -$1.37M | SELL | -8.07% | 211.86K | Jan 22 | View |
| May 15, 2017 | Jon Giacomin | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $57.23 | -$727.65K | SELL-OPTIONS | 0.00% | 32.17K | May 12 | View |
| Feb 13, 2017 | George Barrett | CHAIRMAN AND CEO | 0.00 | $54.09 | -$10.09M | SELL-OPTIONS | 0.00% | 464.23K | Feb 10 | View |
| Nov 14, 2016 | George Barrett | CHAIRMAN AND CEO | 0.00 | $51.12 | -$8.80M | SELL-OPTIONS | 0.00% | 464.23K | Nov 10 | View |
| Aug 22, 2016 | STUART LAWS | SVP & CHIEF ACCOUNTING OFFICER | -9.70K | $82.45 | -$800.01K | SELL | -78.12% | 2.72K | Aug 18 | View |
| Aug 22, 2016 | PATRICIA MORRISON | CHIEF INFORMATION OFFICER | 0.00 | $61.16 | -$1.88M | SELL-OPTIONS | 0.00% | 55.70K | Aug 18 | View |
| Aug 17, 2016 | Jon Giacomin | CEO, PHARMACEUTICAL SEGMENT | -163.00 | $55.52 | -$3.13M | SELL | -0.49% | 33.02K | Aug 15 - Aug 16 | View |
| Aug 15, 2016 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | -12.70K | $83.13 | -$1.06M | SELL | -12.27% | 90.81K | Aug 11 | View |
| Aug 10, 2016 | George Barrett | CHAIRMAN AND CEO | 0.00 | $57.29 | -$13.17M | SELL-OPTIONS | 0.00% | 490.33K | Aug 08 - Aug 10 | View |
| Aug 10, 2016 | Donald Casey Jr | CEO, MEDICAL SEGMENT | 0.00 | $62.09 | -$2.55M | SELL-OPTIONS | 0.00% | 138.32K | Aug 09 - Aug 10 | View |
| May 23, 2016 | CAROLE WATKINS | CHIEF HR OFFICER | 0.00 | $52.31 | -$4.23M | SELL-OPTIONS | 0.00% | 33.99K | May 20 | View |
| Nov 12, 2015 | George Barrett | CHAIRMAN AND CEO | 0.00 | $57.51 | -$3.30M | SELL-OPTIONS | 0.00% | 406.13K | Nov 10 | View |
| Nov 09, 2015 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | -75.00 | $69.80 | -$1.07M | SELL | -0.22% | 33.63K | Aug 28 - Nov 06 | View |
| Aug 20, 2015 | George Barrett | CHAIRMAN AND CEO | 0.00 | $55.19 | -$16.74M | SELL-OPTIONS | 0.00% | 406.13K | Aug 20 | View |
| Aug 07, 2015 | DAVID ANDERSON | DIRECTOR | 1.40K | $86.41 | $120.97K | BUY | ∞ | 400.00 | Aug 06 | View |
| May 12, 2015 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | 0.00 | $63.45 | -$1.79M | SELL-OPTIONS | 0.00% | 29.06K | May 12 | View |
| May 12, 2015 | George Barrett | CHAIRMAN AND CEO | 0.00 | $56.86 | -$17.75M | SELL-OPTIONS | 0.00% | 348.69K | May 11 | View |
| May 12, 2015 | PATRICIA MORRISON | CHIEF INFORMATION OFFICER | 0.00 | $63.91 | -$1.61M | SELL-OPTIONS | 0.00% | 30.80K | May 08 | View |
| Mar 04, 2015 | CALVIN DARDEN | DIRECTOR | 0.00 | $58.32 | -$578.75K | SELL-OPTIONS | 0.00% | 22.77K | Mar 03 | View |
| Mar 04, 2015 | RICHARD NOTEBAERT | DIRECTOR | 0.00 | $58.50 | -$582.18K | SELL-OPTIONS | 0.00% | 35.78K | Mar 03 | View |
| Mar 04, 2015 | Colleen Arnold | DIRECTOR | 0.00 | $58.23 | -$576.79K | SELL-OPTIONS | 0.00% | 21.60K | Mar 04 | View |
| Feb 23, 2015 | CAROLE WATKINS | CHIEF HR OFFICER | 0.00 | $57.14 | -$2.02M | SELL-OPTIONS | 0.00% | 31.87K | Feb 20 | View |
| Feb 11, 2015 | CAROLE WATKINS | CHIEF HR OFFICER | -81.00 | $56.14 | -$2.93M | SELL | -0.25% | 31.87K | Nov 24 - Feb 10 | View |
| Feb 11, 2015 | George Barrett | CHAIRMAN AND CEO | -24.39K | $56.08 | -$17.27M | SELL | -6.54% | 348.69K | Dec 03 - Feb 10 | View |
| Nov 10, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -2.18K | $61.71 | -$973.45K | SELL | -9.65% | 20.41K | Nov 07 | View |
| Sep 08, 2014 | CAROLE WATKINS | CHIEF HR OFFICER | 0.00 | $58.05 | -$1.38M | SELL-OPTIONS | 0.00% | 31.94K | Sep 05 | View |
| Sep 05, 2014 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $58.03 | -$1.70M | SELL-OPTIONS | 0.00% | 118.58K | Sep 04 | View |
| Aug 28, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 0.00 | $62.06 | -$561.63K | SELL-OPTIONS | 0.00% | 67.19K | Aug 27 | View |
| Aug 26, 2014 | DAVID KING | DIRECTOR | -30.00 | $73.55 | -$2.21K | SELL | -0.25% | 12.10K | Aug 25 | View |
| Aug 19, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -5.22K | $72.14 | -$587.38K | SELL | -18.79% | 22.59K | Aug 15 - Aug 18 | View |
| Aug 19, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -5.81K | $56.36 | -$4.20M | SELL | -7.96% | 67.19K | Aug 15 - Aug 18 | View |
| Aug 19, 2014 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -8.82K | $72.11 | -$1.48M | SELL | -6.92% | 118.58K | Aug 15 - Aug 18 | View |
| Aug 11, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -24.17K | $55.33 | -$4.39M | SELL | -24.87% | 73.00K | Aug 08 | View |
| Aug 11, 2014 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | -4.97K | $55.52 | -$1.46M | SELL | -6.75% | 68.76K | Aug 08 | View |
| Jul 28, 2014 | STUART LAWS | SVP & CHIEF ACCOUNTING OFFICER | 0.00 | $51.72 | -$883.81K | SELL-OPTIONS | 0.00% | 5.78K | Jul 24 | View |
| Jul 28, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | 0.00 | $57.18 | -$750.12K | SELL-OPTIONS | 0.00% | 24.42K | Jul 24 | View |
| Jul 15, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -23.63K | $70.65 | -$1.67M | SELL | -22.07% | 83.46K | Jul 14 | View |
| May 20, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -4.70K | $66.50 | -$312.75K | SELL | -16.15% | 24.42K | May 19 | View |
| May 14, 2014 | George Barrett | CHAIRMAN AND CEO | 0.00 | $54.60 | -$175.73K | SELL-OPTIONS | 0.00% | 334.10K | May 12 | View |
| May 14, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -2.82K | $66.50 | -$187.66K | SELL | -8.84% | 29.12K | May 13 | View |
| May 08, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -27.03K | $63.83 | -$1.73M | SELL | -20.15% | 107.10K | May 07 | View |
| Feb 11, 2014 | George Barrett | CHAIRMAN AND CEO | 0.00 | $55.40 | -$4.50M | SELL-OPTIONS | 0.00% | 334.10K | Feb 10 | View |
| Feb 11, 2014 | CAROLE WATKINS | CHIEF HR OFFICER | -28.26K | $67.01 | -$1.89M | SELL | -50.57% | 27.62K | Feb 07 | View |
| Feb 11, 2014 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $48.23 | -$14.96M | SELL-OPTIONS | 0.00% | 115.97K | Feb 10 - Feb 11 | View |
| Feb 11, 2014 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -2.33K | $68.53 | -$159.67K | SELL | -6.80% | 31.94K | Feb 11 | View |
| Feb 05, 2014 | RICHARD NOTEBAERT | DIRECTOR | 0.00 | $53.81 | -$254.60K | SELL-OPTIONS | 0.00% | 33.75K | Feb 04 | View |
| Feb 05, 2014 | GREGORY KENNY | DIRECTOR | 0.00 | $51.05 | -$521.10K | SELL-OPTIONS | 0.00% | 19.58K | Feb 05 | View |
| Feb 05, 2014 | JOHN FINN | DIRECTOR | -2.25K | $53.81 | -$254.60K | SELL | -9.66% | 21.02K | Dec 20 - Feb 04 | View |
| Feb 05, 2014 | CALVIN DARDEN | DIRECTOR | 0.00 | $54.85 | -$111.77K | SELL-OPTIONS | 0.00% | 20.74K | Feb 05 | View |
| Feb 05, 2014 | Colleen Arnold | DIRECTOR | 0.00 | $56.01 | -$156.24K | SELL-OPTIONS | 0.00% | 19.57K | Feb 04 | View |
| Feb 05, 2014 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | -10.00K | $53.33 | -$849.47K | SELL | -29.21% | 24.24K | Feb 04 | View |
| Feb 05, 2014 | CAROLE WATKINS | CHIEF HR OFFICER | -358.00 | $48.63 | -$1.59M | SELL | -0.64% | 55.87K | Feb 03 - Feb 04 | View |
| Feb 05, 2014 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | -13.17K | $54.03 | -$1.25M | SELL | -16.15% | 68.39K | Feb 03 | View |
| Feb 05, 2014 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -33.10K | $49.06 | -$10.20M | SELL | -19.79% | 134.13K | Feb 03 | View |
| Nov 12, 2013 | George Barrett | CHAIRMAN AND CEO | 0.00 | $52.56 | -$4.06M | SELL-OPTIONS | 0.00% | 334.10K | Nov 11 | View |
| Oct 01, 2013 | STUART LAWS | SVP & CHIEF ACCOUNTING OFFICER | -989.00 | $40.54 | -$599.30K | SELL | -14.62% | 5.78K | Sep 30 | View |
| Sep 12, 2013 | Mark Blake | EVP - STRATEGY & CORP. DEV. | 3.63K | $41.23 | -$187.97K | SELL-OPTIONS | 11.85% | 34.27K | Sep 11 | View |
| Aug 20, 2013 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -4.92K | $51.27 | -$252.50K | SELL | -13.85% | 30.64K | Aug 19 | View |
| Aug 19, 2013 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | -18.67K | $51.42 | -$1.16M | SELL | -18.63% | 81.55K | Aug 14 - Aug 16 | View |
| Aug 19, 2013 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | -8.04K | $51.64 | -$644.88K | SELL | -19.01% | 34.24K | Aug 15 - Aug 16 | View |
| Aug 15, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 1.42K | $50.62 | -$79.79K | SELL-OPTIONS | 0.85% | 167.39K | Aug 13 | View |
| Aug 15, 2013 | George Barrett | CHAIRMAN AND CEO | -75.00K | $52.09 | -$3.91M | SELL | -18.71% | 325.79K | Aug 13 | View |
| Aug 12, 2013 | CALVIN DARDEN | DIRECTOR | 0.00 | $48.98 | -$16.24K | SELL-OPTIONS | 0.00% | 18.13K | Aug 08 | View |
| Aug 07, 2013 | Mark Blake | EVP - STRATEGY & CORP. DEV. | 7.26K | $41.23 | -$375.87K | SELL-OPTIONS | 28.50% | 32.74K | Aug 05 | View |
| Jul 29, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 23.22K | $39.14 | -$1.19M | SELL-OPTIONS | 17.61% | 155.08K | Jul 26 | View |
| Jul 22, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 756.00 | $49.28 | -$44.52K | SELL-OPTIONS | 0.58% | 131.87K | Jul 18 | View |
| Jul 17, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 193.00 | $49.28 | -$11.29K | SELL-OPTIONS | 0.15% | 131.11K | Jul 15 | View |
| Jul 15, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | 23.63K | $38.14 | -$1.16M | SELL-OPTIONS | 22.03% | 130.92K | Jul 11 | View |
| Jun 20, 2013 | JOHN FINN | DIRECTOR | -2.81K | $46.51 | -$169.66K | SELL | -10.79% | 23.27K | Jun 19 | View |
| May 29, 2013 | JEAN SPAULDING | DIRECTOR | 186.00 | $46.24 | -$10.30K | SELL-OPTIONS | 1.09% | 17.18K | May 24 - May 28 | View |
| May 23, 2013 | RICHARD NOTEBAERT | DIRECTOR | 57.00 | $47.30 | -$2.50K | SELL-OPTIONS | 0.18% | 31.14K | May 22 | View |
| May 23, 2013 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -36.00 | $47.52 | -$1.71K | SELL | -0.03% | 104.33K | May 22 | View |
| May 21, 2013 | CAROLE WATKINS | CHIEF HR OFFICER | 1.88K | $35.45 | -$72.66K | SELL-OPTIONS | 4.13% | 47.45K | May 20 | View |
| May 21, 2013 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | 14.45K | $37.64 | -$558.28K | SELL-OPTIONS | 17.86% | 95.33K | May 20 | View |
| May 21, 2013 | JEAN SPAULDING | DIRECTOR | -1.67K | $47.90 | -$79.80K | SELL | -8.93% | 17.00K | May 20 | View |
| May 15, 2013 | SMITH CARRIE COX | DIRECTOR | 435.00 | $46.25 | $20.12K | BUY | 3.18% | 14.13K | May 14 | View |
| May 08, 2013 | CAROLE WATKINS | CHIEF HR OFFICER | -21.39K | $34.42 | -$1.05M | SELL | -31.95% | 45.57K | May 06 - May 07 | View |
| May 08, 2013 | Mark Blake | EVP - STRATEGY & CORP. DEV. | 7.53K | $36.95 | -$347.60K | SELL-OPTIONS | 41.91% | 25.48K | May 07 | View |
| May 08, 2013 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | -14.25K | $46.14 | -$657.63K | SELL | -26.48% | 39.58K | May 06 | View |
| May 08, 2013 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | 10.79K | $36.71 | -$571.00K | SELL-OPTIONS | 15.40% | 80.88K | May 07 - May 08 | View |
| May 08, 2013 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -2.63K | $40.06 | -$2.63M | SELL | -2.39% | 107.28K | May 06 - May 07 | View |
| May 08, 2013 | RICHARD NOTEBAERT | DIRECTOR | 0.00 | $44.73 | -$15.20K | SELL-OPTIONS | 0.00% | 31.08K | May 06 | View |
| May 08, 2013 | JEAN SPAULDING | DIRECTOR | 0.00 | $43.78 | -$50.30K | SELL-OPTIONS | 0.00% | 18.66K | May 06 | View |
| Jan 25, 2013 | Craig Morford | CHIEF LEGAL/COMPLIANCE OFFICER | 13.17K | $36.14 | -$477.90K | SELL-OPTIONS | 23.13% | 70.09K | Jan 23 | View |
| Jan 25, 2013 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -3.50K | $36.12 | -$1.12M | SELL | -3.25% | 104.36K | Dec 03 - Jan 23 | View |
| Jan 25, 2013 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | 10.88K | $36.14 | -$395.06K | SELL-OPTIONS | 25.35% | 53.83K | Jan 23 | View |
| Jan 14, 2013 | Falk Stephen | EVP, GEN. COUNSEL & CORP. SEC. | 10.10K | $35.14 | -$350.74K | SELL-OPTIONS | 30.74% | 42.95K | Jan 10 | View |
| Jan 14, 2013 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -1.47K | $42.92 | -$63.14K | SELL | -7.57% | 17.95K | Jan 10 | View |
| Dec 17, 2012 | Mark Blake | EVP - STRATEGY & CORP. DEV. | -2.33K | $42.25 | -$98.44K | SELL | -10.71% | 19.43K | Dec 14 | View |
| Nov 05, 2012 | STUART LAWS | SVP & CHIEF ACCOUNTING OFFICER | -2.56K | $41.22 | -$105.69K | SELL | -33.24% | 5.15K | Nov 01 | View |
| Oct 09, 2012 | Jeffrey W. Henderson | CHIEF FINANCIAL OFFICER | 3.77K | $33.64 | -$484.54K | SELL-OPTIONS | 3.56% | 109.91K | Oct 04 | View |
| Sep 11, 2012 | William Jeffrey Henderson | CHIEF FINANCIAL OFFICER | -29.41K | $32.81 | -$1.68M | SELL | -21.05% | 110.28K | Sep 07 - Sep 10 | View |
| May 21, 2012 | JEAN SPAULDING | DIRECTOR | 1.67K | $35.43 | -$59.89K | SELL-OPTIONS | 12.13% | 15.41K | May 17 | View |
| Feb 29, 2012 | Michael Lynch | CEO, MEDICAL SEGMENT | 8.03K | $34.64 | -$242.44K | SELL-OPTIONS | 9.89% | 89.20K | Feb 27 | View |
| Feb 27, 2012 | Michael Lynch | CEO, MEDICAL SEGMENT | -8.00K | $36.93 | -$632.83K | SELL | -8.97% | 81.18K | Feb 24 | View |
| Oct 28, 2011 | Michael C Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 11.99K | $36.12 | -$434.96K | SELL-OPTIONS | 15.24% | 90.68K | Oct 26 - Oct 27 | View |
| Oct 20, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | -1.34K | $42.40 | -$56.86K | SELL | -17.34% | 6.39K | Oct 19 | View |
| Sep 15, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | -1.50K | $41.23 | -$61.68K | SELL | -16.21% | 7.73K | Sep 14 - Sep 15 | View |
| Aug 17, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | 143.00 | $41.54 | -$70.46K | GRANT | 1.57% | 9.23K | Aug 15 - Aug 17 | View |
| Jul 14, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | -1.10K | $46.68 | -$51.35K | SELL | -10.80% | 9.09K | Jul 13 | View |
| Jul 08, 2011 | Stephen T. Falk | EVP, GEN. COUNSEL & CORP. SEC. | 2.50K | $39.20 | -$95.07K | SELL-OPTIONS | 11.34% | 24.51K | Jul 07 | View |
| Jul 08, 2011 | JOHN FINN | DIRECTOR | -2.86K | $46.50 | -$133.18K | SELL | -6.91% | 38.56K | Jul 06 | View |
| Jul 05, 2011 | Carole S Watkins | CHIEF HR OFFICER | 2.58K | $34.45 | -$95.69K | SELL-OPTIONS | 4.72% | 57.14K | Jul 01 | View |
| Jul 05, 2011 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $39.14 | -$138.15K | SELL-OPTIONS | 0.00% | 62.19K | Jul 01 | View |
| Jun 16, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | -1.10K | $43.79 | -$48.17K | SELL | -9.75% | 10.19K | Jun 15 | View |
| May 20, 2011 | Jeffrey W. Henderson | CHIEF FINANCIAL OFFICER | -10.55K | $42.47 | -$740.87K | SELL | -8.61% | 112.05K | May 19 | View |
| May 13, 2011 | Stuart G Laws | SVP & CHIEF ACCOUNTING OFFICER | -1.02K | $44.96 | -$46.08K | SELL | -8.33% | 11.29K | May 11 | View |
| May 09, 2011 | Stephen T. Falk | EVP, GEN. COUNSEL & CORP. SEC. | -3.52K | $33.95 | -$234.22K | SELL | -13.77% | 22.02K | May 05 | View |
| May 09, 2011 | Michael C Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $38.64 | -$128.00K | SELL-OPTIONS | 0.00% | 62.19K | May 05 | View |
| Apr 27, 2011 | Michael C Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $38.14 | -$117.86K | SELL-OPTIONS | 0.00% | 62.19K | Apr 27 | View |
| Apr 27, 2011 | Stephen T. Falk | EVP, GEN. COUNSEL & CORP. SEC. | 786.00 | $32.95 | -$27.57K | SELL-OPTIONS | 3.18% | 25.53K | Apr 26 | View |
| Apr 27, 2011 | Jeffrey W. Henderson | CHIEF FINANCIAL OFFICER | 0.00 | $41.34 | -$196.00K | SELL-OPTIONS | 0.00% | 122.60K | Apr 26 | View |
| Apr 25, 2011 | Michael C Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -8.56K | $42.95 | -$367.65K | SELL | -12.10% | 62.19K | Apr 21 | View |
| Mar 21, 2011 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | 0.00 | $31.93 | -$3.19K | SELL-OPTIONS | 0.00% | 70.75K | Mar 18 | View |
| Feb 08, 2011 | Michael C Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -6.90K | $33.81 | -$1.56M | SELL | -8.88% | 70.75K | Feb 07 | View |
| Dec 07, 2010 | Michael Kaufmann | CEO, PHARMACEUTICAL SEGMENT | -633.00 | $37.29 | -$23.60K | SELL | -95.19% | 32.00 | Dec 03 | View |
| Aug 24, 2009 | Carole S Watkins | CHIEF HR OFFICER | 0.00 | $32.92 | -$46.17K | SELL-OPTIONS | 0.00% | 41.13K | Aug 20 | View |
| Aug 24, 2009 | RICHARD NOTEBAERT | DIRECTOR | 0.00 | $33.92 | -$6.46K | SELL-OPTIONS | 0.00% | 16.32K | Aug 20 | View |
| Aug 24, 2009 | JOHN FINN | DIRECTOR | 461.00 | $32.38 | -$148.57 | SELL-OPTIONS | 1.26% | 37.09K | Aug 20 | View |
| Nov 27, 2007 | R. Kerry Clark | CHAIRMAN AND CEO | 20.00K | $57.50 | $1.15M | BUY | 13.10% | 172.68K | Nov 26 | View |
| Nov 16, 2007 | MATTHEW WALTER | DIRECTOR | -58.90K | $59.92 | -$3.53M | SELL | -6.09% | 907.66K | Nov 14 | View |
| Nov 16, 2007 | MATTHEW WALTER | DIRECTOR | -36.10K | $60.19 | -$1.87M | SELL | -3.34% | 1.05M | Nov 13 - Nov 14 | View |
| Jun 06, 2007 | Eric Slusser | EVP, CAO & CONTROLLER | 0.00 | $65.35 | -$290.86K | SELL-OPTIONS | 0.00% | 8.57K | Jun 04 | View |
| Jun 06, 2007 | Matthew D Walter | DIRECTOR | -7.00K | $72.73 | -$508.89K | SELL | -6.81% | 95.72K | Jun 04 | View |
| Apr 23, 2007 | Carole S Watkins | CHIEF HR OFFICER | 0.00 | $56.88 | -$203.73K | SELL-OPTIONS | 0.00% | 14.21K | Apr 20 | View |
| Apr 04, 2007 | David L Schlotterbeck | CEO - PHARM & MED PRODUCTS | -375.00 | $73.00 | -$27.38K | SELL | -24.15% | 1.18K | Apr 02 | View |
| Mar 01, 2007 | Jean G Spaulding | DIRECTOR | -485.00 | $70.21 | -$34.05K | SELL | -43.77% | 623.00 | Mar 01 | View |
| Feb 13, 2007 | John B McCoy | DIRECTOR | 27.98K | $52.03 | -$112.69K | SELL-OPTIONS | 100.57% | 55.80K | Dec 07 - Feb 12 | View |
| Feb 13, 2007 | Robert L Gerbig | DIRECTOR | 0.00 | $51.84 | -$257.69K | SELL-OPTIONS | 0.00% | 66.22K | Feb 12 - Feb 13 | View |
| Jan 29, 2007 | Matthew D Walter | DIRECTOR | -23.13K | $72.50 | -$1.81M | SELL | -20.12% | 91.80K | Jan 09 - Jan 25 | View |
| Dec 15, 2006 | Robert D Walter | EXEC. CHAIRMAN THE BOARD | 0.00 | $46.11 | -$762.42K | SELL-OPTIONS | 0.00% | 1.64M | Dec 14 - Dec 15 | View |
| Dec 13, 2006 | Robert D Walter | EXEC. CHAIRMAN THE BOARD | 0.00 | $46.42 | -$774.58K | SELL-OPTIONS | 0.00% | 1.64M | Dec 12 - Dec 13 | View |
| Dec 11, 2006 | Matthew D Walter | DIRECTOR | -90.00K | $65.90 | -$5.93M | SELL | -7.48% | 1.11M | Dec 11 | View |
| Dec 11, 2006 | Robert D Walter | EXEC. CHAIRMAN THE BOARD | -2.13K | $46.48 | -$388.46K | SELL | -0.13% | 1.64M | Aug 30 - Dec 11 | View |
| Dec 04, 2006 | Matthew D Walter | DIRECTOR | -10.00K | $65.77 | -$657.65K | SELL | -5.47% | 172.80K | Dec 04 | View |
| Aug 22, 2006 | Brendan A Ford | EVP-CORPORATE DEVELOPMENT | 0.00 | $47.32 | -$419.50K | SELL-OPTIONS | 0.00% | 90.23K | Aug 18 - Aug 21 | View |
| Aug 22, 2006 | David L Schlotterbeck | CEO - PHARM & MED PRODUCTS | -20.00K | $67.51 | -$1.35M | SELL | -29.27% | 48.32K | Aug 18 | View |
| May 18, 2006 | Ronald K Labrum | CEO-SUPPLY CHAIN SVCS. | 0.00 | $49.73 | -$1.39M | SELL-OPTIONS | 0.00% | 38.90K | May 16 | View |
| May 18, 2006 | Carole S Watkins | EVP - HUMAN RESOURCES | -210.00 | $68.01 | -$11.90K | SELL | -4.46% | 4.50K | Mar 20 - May 16 | View |
| May 17, 2006 | Matthew D Walter | DIRECTOR | -5.30K | $67.80 | -$474.40K | SELL | -6.35% | 78.13K | Jan 11 - May 15 | View |
| Feb 09, 2006 | George L Fotiades | PRESIDENT & COO | 39.00 | $62.76 | $2.45K | BUY | 0.05% | 80.28K | Oct 15 - Jan 15 | View |
| Feb 01, 2006 | Ronald K Labrum | CEO-HEALTHCARE SUPPLY CHN SVC | 0.00 | $42.18 | -$1.17M | SELL-OPTIONS | 0.00% | 38.90K | Feb 01 | View |
| Dec 06, 2005 | Ronald K Labrum | CEO-HEALTHCARE SUPPLY CHN SVC | 0.00 | $37.42 | -$2.55M | SELL-OPTIONS | 0.00% | 38.90K | Dec 05 | View |
| Nov 30, 2005 | David L Schlotterbeck | CHMN & CEO-CLNCL TECHN & SVCS | -32.00K | $64.30 | -$2.06M | SELL | -32.52% | 66.41K | Nov 30 | View |
| Nov 03, 2005 | Mark W Parrish | COO-PHARM SUPPLY CHN SVCS | 0.00 | $39.88 | -$69.30K | SELL-OPTIONS | 0.00% | 25.16K | Nov 01 | View |
| Oct 27, 2005 | Ronald K Labrum | CEO-HEALTHCARE SUPPLY CHN SVC | 0.00 | $37.42 | -$55.71K | SELL-OPTIONS | 0.00% | 38.90K | Oct 25 | View |
| Oct 05, 2005 | Mark W Parrish | COO-PHARM SUPPLY CHN SVCS | 0.00 | $40.47 | -$71.14K | SELL-OPTIONS | 0.00% | 25.16K | Oct 03 | View |
| Sep 12, 2005 | Robert D Walter | CHAIRMAN AND CEO | -10.00K | $59.60 | -$596.00K | SELL | -0.44% | 2.27M | Sep 12 | View |
| Sep 06, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 7.44K | $38.53 | -$65.08K | SELL-OPTIONS | 41.98% | 25.16K | Sep 01 - Sep 02 | View |
| Aug 10, 2005 | Robert D Walter | CHAIRMAN AND CEO | -65.00K | $59.15 | -$3.84M | SELL | -2.83% | 2.23M | Aug 10 | View |
| Aug 03, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $38.70 | -$65.60K | SELL-OPTIONS | 0.00% | 17.72K | Aug 01 | View |
| Jul 11, 2005 | Robert D Walter | CHAIRMAN AND CEO | -65.00K | $57.97 | -$3.77M | SELL | -2.75% | 2.29M | Jul 11 | View |
| Jul 06, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $37.63 | -$62.26K | SELL-OPTIONS | 0.00% | 17.72K | Jul 01 | View |
| Jun 22, 2005 | Ronald K Labrum | CEO-INT PROV SOL & CAH INT'L | 0.00 | $34.92 | -$2.37M | SELL-OPTIONS | 0.00% | 14.38K | Jun 20 | View |
| Jun 10, 2005 | Robert D Walter | CHAIRMAN AND CEO | -65.00K | $57.31 | -$3.72M | SELL | -2.68% | 2.36M | Jun 10 | View |
| Jun 03, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $37.83 | -$62.88K | SELL-OPTIONS | 0.00% | 17.72K | Jun 01 | View |
| May 31, 2005 | George L Fotiades | PRESIDENT & COO | 0.00 | $48.03 | -$1.43M | SELL-OPTIONS | 0.00% | 80.40K | May 31 | View |
| May 10, 2005 | Robert D Walter | CHAIRMAN AND CEO | -99.50K | $55.66 | -$3.62M | SELL | -3.94% | 2.42M | Apr 23 - May 10 | View |
| May 05, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $36.87 | -$59.88K | SELL-OPTIONS | 0.00% | 17.72K | May 04 | View |
| Apr 11, 2005 | Robert D Walter | CHAIRMAN AND CEO | -65.00K | $55.52 | -$3.61M | SELL | -2.71% | 2.33M | Apr 11 | View |
| Apr 06, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $36.87 | -$59.88K | SELL-OPTIONS | 0.00% | 17.72K | Apr 04 | View |
| Mar 10, 2005 | Robert D Walter | CHAIRMAN AND CEO | -65.00K | $57.21 | -$3.72M | SELL | -2.35% | 2.70M | Mar 10 | View |
| Mar 02, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 0.00 | $38.19 | -$64.02K | SELL-OPTIONS | 0.00% | 17.72K | Mar 01 | View |
| Feb 22, 2005 | Mark W Parrish | CHMN & CEO-PDPS | 8.95K | $35.98 | -$247.17K | SELL-OPTIONS | 101.94% | 17.72K | Feb 17 | View |
| Feb 17, 2005 | John F Havens | DIRECTOR | -9.57K | $57.47 | -$549.98K | SELL | -24.54% | 29.43K | Feb 16 | View |
| Feb 17, 2005 | Jody R Davids | EVP & CIO | 0.00 | $44.93 | -$119.70K | SELL-OPTIONS | 0.00% | 1.71K | Feb 16 | View |
| Feb 16, 2005 | Matthew D Walter | DIRECTOR | -5.85K | $57.00 | -$443.18K | SELL | -4.27% | 131.10K | Feb 14 - Feb 16 | View |
| Feb 07, 2005 | Brendan A Ford | EVP - CORP. DEVELOPMENT | 3.87K | $37.33 | -$226.98K | SELL-OPTIONS | 6.20% | 66.25K | Feb 03 | View |
| Dec 08, 2004 | Ronald K Labrum | CEO-INT PROV SOL & CAH INT'L | 0.00 | $30.87 | -$1.99M | SELL-OPTIONS | 0.00% | 14.38K | Dec 06 | View |
| Nov 12, 2004 | George L Fotiades | PRESIDENT & COO | 38.13K | $39.07 | -$1.66M | SELL-OPTIONS | 90.18% | 80.40K | Nov 10 | View |
| Aug 25, 2004 | Brendan A Ford | EVP - CORP. DEVELOPMENT | 40.00 | $43.77 | $1.75K | BUY | 0.06% | 62.38K | Aug 02 | View |
| May 04, 2004 | Gary S Jensen | SVP - CORPORATE CONTROLLER | 0.00 | $50.42 | -$295.89K | SELL-OPTIONS | 0.00% | 612.00 | May 03 | View |
| Mar 10, 2004 | Gary S Jensen | SVP - CORPORATE CONTROLLER | 0.00 | $46.02 | -$185.87K | SELL-OPTIONS | 0.00% | 612.00 | Mar 08 | View |
| Mar 05, 2004 | John B McCoy | DIRECTOR | 0.00 | $40.12 | -$195.83K | SELL-OPTIONS | 0.00% | 50.77K | Mar 04 | View |
| Feb 25, 2004 | Jean G Spaulding | DIRECTOR | 150.00 | $64.10 | $9.62K | BUY | 15.32% | 1.13K | Feb 24 | View |
| Feb 25, 2004 | Stephen S Thomas | EVP-GROUP PRES.-AIS | 0.00 | $47.67 | -$1.45M | SELL-OPTIONS | 0.00% | 33.01K | Feb 24 | View |
| Feb 24, 2004 | Brendan A Ford | EVP - CORP. DEVELOPMENT | -4.85K | $37.58 | -$944.49K | SELL | -8.86% | 49.92K | Feb 23 | View |
| Jan 28, 2004 | Mark W Parrish | EVP; GROUP PRES.-PHARM. DISTR | 0.00 | $37.60 | -$408.12K | SELL-OPTIONS | 0.00% | 1.95K | Jan 26 | View |
| Jan 28, 2004 | Jody R Davids | EVP & CHIEF INFORMATION OFFCR. | 0.00 | $48.68 | -$157.20K | SELL-OPTIONS | 0.00% | 620.00 | Jan 26 | View |
| Aug 06, 2003 | David W Raisbeck | DIRECTOR | 2.18K | $56.39 | $122.75K | BUY | ∞ | 978.00 | Aug 04 - Aug 05 | View |
| Aug 05, 2003 | Robert D Walter | CHAIRMAN AND CEO | 40.00K | $56.91 | $2.28M | BUY | 3.39% | 1.22M | Aug 04 | View |
FAQ
Q
L'insider trading è legale?
A
L'insider trading è legale a condizione che gli insider segnalino le loro operazioni alla SEC. Il trading illegale di titoli si verifica quando l'insider viola un dovere fiduciario o non segnala le sue operazioni.
Q
Quali sono alcuni esempi di manipolazione del mercato?
A
L'insider trading, gli schemi di pump and dump, il front running e i wash trade sono tutti esempi di manipolazione del mercato. Gli investitori che seguono i movimenti delle attività degli insider dovrebbero riflettere attentamente sul motivo per cui questi insider stanno negoziando le loro azioni prima di procedere.
CAH Notizie di insider trading
Le persone guardano anche
Sfoglia insider trading su tutte le azioni.
Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende
Dati di mercato forniti da API Benzinga
PARTNER/COLLABORATORE
© 2026 Benzinga | All Rights Reserved